Trial reportCNS spectrums2009
A prospective pilot study of levetiracetam for body dysmorphic disorder.
Trial report in CNS spectrums, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Effects of Pharmacological and Psychological Treatments on Depressive Symptoms in Body Dysmorphic Disorder: A Systematic Review and Meta-Analysis.Current psychiatry reports · 2026Pooled it
- Body Dysmorphic Disorder: Clinical Overview and Relationship to Obsessive-Compulsive Disorder.Focus (American Psychiatric Publishing) · 2021Article
- Association of Body Dysmorphic Disorder with Leptin Levels in Patients with Normal Weight Undergoing Liposuction: A Matched Case Study.Plastic and reconstructive surgery. Global open · 2019Article
- Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5.CNS spectrums · 2014Review
- Age at onset and clinical correlates in body dysmorphic disorder.Comprehensive psychiatry · 2013Article
- Symmetry Concerns as a Symptom of Body Dysmorphic Disorder.Journal of obsessive-compulsive and related disorders · 2013Article
- Psychometric evaluation of the Brown Assessment of Beliefs Scale in body dysmorphic disorder.The Journal of nervous and mental disease · 2013Article
- Pharmacotherapy for Body Dysmorphic Disorder.Psychiatric annals · 2010Article
- Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?Depression and anxiety · 2010Review
- Body dysmorphic disorder.Dialogues in clinical neuroscience · 2010Review
- Olfactory reference syndrome: demographic and clinical features of imagined body odor.General hospital psychiatryArticle
- Cosmetic Presentations and Challenges of Body Dysmorphic Disorder and Its Collaborative Management.Journal of cutaneous and aesthetic surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionBody dysmorphic disorder (BDD) is an often severe disorder, but few treatment studies have been conducted.
objectiveThis pilot study explored the efficacy and safety of the antiepileptic medication levetiracetam for BDD.
methodsSeventeen subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition BDD participated in a 12-week open-label levetiracetam trial. Subjects were assessed at regular intervals with standard measures.
resultsIn intent-to-treat analyses, scores on the Yale-Brown Obsessive Compulsive Scale Modified for BDD (BDD-YBOCS), the primary outcome measure, decreased from 32.5+/-4.7 at baseline to 21.5+/-11.0 at endpoint (P<.001). Approximately 60% (n=9) of subjects were responders (>30% decrease on the BDD-YBOCS). The mean time to response was 4.6+/-2.8 (range: 2-10) weeks. Scores also significantly improved on the Brown Assessment of Beliefs Scale, the Hamilton Rating Scale for Depression, the Global Assessment of Functioning Scale, and the Social and Occupational Functioning Assessment Scale. Scores did not significantly improve on the Quality of Life Enjoyment and Satisfaction Questionnaire, the Beck Anxiety Inventory, or the Social Phobia Inventory. The mean endpoint dose of levetiracetam was 2,044.1+/-1,065.2 (range: 250-3,000) mg/day, and it was relatively well-tolerated.
conclusionRandomized, double-blind placebo-controlled studies of levetiracetam for BDD are needed to confirm these preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.